2015ASCO靶向治疗新进展 张力 教授［PPT课件］.pptVIP

张 力 ;2015 ASCO 肺癌分子靶向治疗新进展;晚期NSCLC治疗已经进入到基因分型的个体化时代;EGFR-TKI的进展;比较阿法替尼与厄洛替尼用于晚期肺鳞癌含铂化疗失败后的二线治疗：来自全球III期研究LUX-Lung(LL8)的生存数据(OS);Presented By Jean-Charles Soria at 2015 ASCO Annual Meeting;LUX-Lung 8：PFS (独立评估)更新了所有随机入组患者的数据(n=795);Presented By Jean-Charles Soria at 2015 ASCO Annual Meeting;Presented By Jean-Charles Soria at 2015 ASCO Annual Meeting;Presented By Jean-Charles Soria at 2015 ASCO Annual Meeting;突变选择性EGFR抑制剂AZD9291作为一线治疗EGFR突变阳性晚期非小细胞肺癌（NSCLC）：来自一项I期扩展队列的结果;Presented By Suresh Ramalingam at 2015 ASCO Annual Meeting;Presented By Suresh Ramalingam at 2015 ASCO Annual Meeting;Presented By Suresh Ramalingam at 2015 ASCO Annual Meeting;Presented By Suresh Ramalingam at 2015 ASCO Annual Meeting;Presented By Suresh Ramalingam at 2015 ASCO Annual Meeting;Presented By Suresh Ramalingam at 2015 ASCO Annual Meeting;Rociletinib（CO1686）用于伴有T790M突变的非小细胞肺癌患者的疗效;Presented By Lecia Sequist at 2015 ASCO Annual Meeting;Presented By Lecia Sequist at 2015 ASCO Annual Meeting;Presented By Lecia Sequist at 2015 ASCO Annual Meeting;Presented By Lecia Sequist at 2015 ASCO Annual Meeting;Presented By Lecia Sequist at 2015 ASCO Annual Meeting;Presented By Lecia Sequist at 2015 ASCO Annual Meeting;Presented By Lecia Sequist at 2015 ASCO Annual Meeting;Presented By Lecia Sequist at 2015 ASCO Annual Meeting;ALK抑制剂的进展;ALK抑制剂Alectinib治疗克唑替尼治疗失败的ALK+非小细胞肺癌的疗效和安全性：一项开放单臂II期临床研究(NP28673);研究设计;克唑替尼耐药的ALK+ NSCLC的有效率更高;克唑替尼耐药的ALK+NSCLC患者alectinib显示出显著的疗效n=118;Crizotinib治疗耐药的ALK+NSCLC患者有更长的PFS;ALK+伴有CNS转移的NSCLC患者alectinib显示很高的缓解率和疾病控制率;ALK+伴有CNS转移的NSCLC患者alectinib显示很好的活性;ALK+伴有CNS转移的NSCLC患者有较高的缓解率和疾病控制率，未经放疗组更加;3/4度的不良反应很低;3/4度治疗相关的不良反应很少出现;结论;色瑞替尼和克唑替尼治疗既往未经克唑替尼治疗的ALK+晚期或转移性NSCLC患者的疗效比较;研究方法（回顾性）;研究结果：配对前;研究结果－配对??;Brigatinib(AP26113)治疗包括ALK+非小细胞肺癌在内的晚期恶性肿瘤的疗效和安全性;研究设计;Brigatinib对ALK+患者的抗肿瘤活性（n=70）;ALK+ NSCLC患者的疗效评估;ALK+患者的PFS和有效持续时间;ALK+ NSCLC伴颅内转移患者的颅内疗效;Brigatinib对伴有颅内可测量脑转移的ALK+患者的抗肿瘤活性（n=15）;不同剂量组治疗相关不良反应一览表（发生率≥10%）;其他少见靶点的进展;BRAF抑制剂达拉非尼(D)与MEK抑制剂曲美替尼(T)联合治疗BRAF V600E突变转移性非